NCT04129515 2026-01-02
NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis
Brown University
Phase 1/2 Withdrawn
Clinical Trials
22 trialsNCT03167177 2025-02-21
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT02535078 2024-07-24
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
Immunocore Ltd
Phase 1/2 Withdrawn
NCT02143050 2023-11-18
Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
University of Louisville
Phase 1/2 Withdrawn
NCT06090318 2023-10-19
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
Phase 1/2 Withdrawn
NCT04060407 2021-06-01
CINDI
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2 Withdrawn
NCT03111901 2019-07-12
UVA-AM-002
University of Virginia
Phase 1/2 Withdrawn
NCT03297463 2018-08-01
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT03326258 2018-07-18
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT03282188 2018-05-04
REO13 Melanoma With of Without GM-CSF
University of Leeds
Phase 1/2 Withdrawn
NCT02812693 2018-04-05
Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
Ohio State University Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT00769990 2017-12-13
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT02719015 2017-11-24
Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT02736123 2017-09-20
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
University of Pittsburgh
Phase 1/2 Withdrawn
NCT02862145 2016-09-27
MRX34-102
Mirna Therapeutics, Inc.
Phase 1/2 Withdrawn
NCT02065466 2016-04-21
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
University of Arizona
Phase 1/2 Withdrawn
NCT02452281 2016-01-25
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
The University of Texas Health Science Center, Houston
Phase 1/2 Withdrawn
NCT01764009 2015-09-11
AIMM
Valerio Therapeutics
Phase 1/2 Withdrawn
NCT01531244 2014-07-18
Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma
Washington University School of Medicine
Phase 1/2 Withdrawn
NCT01689870 2014-04-01
Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
Ludwig Institute for Cancer Research
Phase 1/2 Withdrawn
NCT01340729 2013-04-05
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT01409187 2012-01-26
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn